Abstract
Focussed studies on imidazopyridine inhibitors of Plasmodium falciparum cyclic GMP-dependent protein kinase (PfPKG) have significantly advanced the series towards desirable in vitro property space. LLE-based approaches towards combining improvements in cell potency, key physicochemical parameters and structural novelty are described, and a structure-based design hypothesis relating to substituent regiochemistry has directed efforts towards key examples with well-balanced potency, ADME and kinase selectivity profiles.
Keywords:
Imidazopyridine; Malaria; Plasmodium falciparum; Protein kinase G; SAR; cGMP.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Cyclic GMP-Dependent Protein Kinases / antagonists & inhibitors*
-
Humans
-
Imidazoles / chemistry*
-
Malaria / drug therapy*
-
Malaria / enzymology
-
Malaria / parasitology
-
Models, Molecular
-
Molecular Docking Simulation
-
Plasmodium falciparum / drug effects*
-
Plasmodium falciparum / enzymology
-
Protein Conformation
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyridines / chemistry*
Substances
-
Bridged Bicyclo Compounds, Heterocyclic
-
Imidazoles
-
Protein Kinase Inhibitors
-
Pyridines
-
imidazopyridine
-
Cyclic GMP-Dependent Protein Kinases